Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams Bevyxxa

→ Swiss phar­ma group Helsinn is ac­quir­ing rights to skin can­cer drug Valchlor (mar­ket­ed as Leda­ga in Eu­rope) from Acte­lion Phar­ma­ceu­ti­cals. The deal gets Helsinn world­wide rights to the rare dis­ease drug, which is a top­i­cal drug for my­co­sis fun­goides-type cu­ta­neous T-cell lym­phoma (MF-CT­CL). Val­chor is an FDA-ap­proved for­mu­la­tion of mechlorethamine. It was launched in the US in 2013, and pulled in $35 mil­lion in an­nu­al glob­al sales in 2017. Helsinn’s US-based sub­sidiary, Helsinn Ther­a­peu­tics, says it will build up its sales force in the re­gion to mar­ket the drug in the US. Fi­nan­cial de­tails of the deal were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER